Enzymotec Ltd.

Enzyomtec Ltd.

Frutarom Ltd

Rassan Zuabi

Avidor Shulman

Gai Ben Dror

Dori Pelled

Zohar Bar-On

Orly Farkash

Dorit Platt

Yael Richter

Dorit Plat

Yael Herzog

Neta Scheinman

Yoni Twito

Sobhi Basheer

Gai Ben-Dror

Fabiana Bar-Yoseph

Asher Widberg

Ran Numa

The invention provides oil blends, processes for the preparation thereof and their uses.

Oil blends, processes for the preparation thereof and their use in formulas

The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids and uses of such preparations.

Glycerophospholipids for the improvement of cognitive functions

Disclosed herein are polar lipid mixtures, comprising glycerophospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidyl-inositol (PI), and sphingolipids such as sphyngomyelin (SM). Most importantly, the ratio of phospholipids in said mixture is comparable to that of HMF, and is represented by SM&#x3e;PC&#x3e;PE&#x3e;PS&#x3e;PI or SM=PC&#x3e;PE&#x3e;PS&#x3e;PI. Processes for the preparation of said mixtures and uses thereof are also described herein.

Polar lipid mixtures, their preparation and uses

The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.

A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.

Lipids containing omega-3 and omega-6 fatty acids

Disclosed are stable PS preparations, in powder, liquid and dispersion forms, as well as methods of producing thereof. Most importantly, the stable PS preparations are particularly devoid of residual phospholipase D activity, and the methods of eliminating such activity are also described herein. Lastly, uses of these PS preparations in nutraceuticals or as active agents of pharmaceutical compositions are also provided herein.

Stabilized formulations of phosphatidylserine

Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease. The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.

Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions

A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidyicholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.

This invention provides a preparation comprising serine glycerophospholipids which comprise a mixture of serine glycerophospholipids comprising eicosapentaenoic acid (EPA) and serine glycerophospholipids comprising docosahexaenoic acid (DHA), wherein each such serine glycerophospholipid comprising EPA and each such serine glycerophospholipid comprising DHA has the formula (I): wherein R&#x2033; is serine; wherein one of R or R' is acyl EPA or acyl DHA and the other of R or R&#x2032; is hydrogen or an acyl group; wherein the combined amount of EPA and DHA present in such mixture of serine glycerophospholipids constitutes 10-50% by weight of the total fatty acids content of the serine glycerophospholipids in said preparation; and wherein the mixture is not identical to naturally occurring human or mammalian brain PS.

A new enzymatic process for preparing 1,2-diacylated phospholipids using an enzyme preparation possessing phospholipase activity towards acylation at the sn-1 and sn-2 sites in a microaqueous reaction system. More particularly, the 1,2-diacyl-phospholipids produced according to the esterification/transesterification process are obtainable in high yield and purity and carry identical desired carboxylic acid, preferably fatty acid, acyl groups at the sn-1 and sn-2 positions. The process involves esterification/transesterification (acylation) of a glycerophospholipid, preferably glycerophosphoryl choline (GPC) with a desired carboxylic acid, preferably fatty acid, or their derivatives in the presence of the above mentioned appropriate enzyme preparation. The process of the invention further relates to a process for the production of 1-acyl-2-lyso-glycerophospholipid, preferably 2-lyso-PC by reacting glycerophospholipid, preferably glycerophosphoryl choline (GPC) with a desired carboxylic acid, preferably fatty acid, or their derivatives in the presence of a sn-1 specific phospholipase (PLAor PLA) and a solvent, in a microaqueous medium.

Growing community of inventors

Kfar Neen, Israel

Rassan Zuabi